Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Contraceptive counselling and medical eligibility

Essential points for quick revision.

Saved on this device
!
Exclude time-critical pregnancy and safeguarding needs

Recent unprotected sex, reproductive coercion, sexual assault, pregnancy symptoms or an interacting medicine can require emergency contraception or urgent assessment before routine method selection.

Action: Establish exposure timing and pregnancy possibility, offer the most effective eligible emergency contraception, address immediate safety and then quick-start ongoing contraception with the correct testing and backup plan.

Synopsis

Use shared decision making and UKMEC 2025 to distinguish method safety from effectiveness, interactions, instructions and patient preferences across contraceptive choices.

  • UKMEC 1 means no restriction; 2 means advantages generally outweigh theoretical or proven risks; 3 means risks usually outweigh advantages and specialist judgement plus alternatives are needed; 4 means an unacceptable health risk and the method should not be used.
  • UKMEC classifies safety for contraceptive use. It does not select the best method, measure efficacy, account for drug interactions or malabsorption, or provide starting and missed-method instructions.
  • Assess pregnancy intention, timing, bleeding goals, STI protection, medical and family history, blood pressure where relevant, smoking, migraine aura, postpartum state, medicines, adherence preferences and ability to stop or remove a method.

Key red flags

Unilateral pelvic pain, collapse, shoulder-tip pain or bleeding with possible pregnancy requires urgent ectopic-pregnancy assessment.

New focal neurology, chest pain, breathlessness or unilateral leg swelling while using oestrogen-containing contraception requires urgent assessment and method review.

Coercion, hidden contraceptive interference, sexual violence or inability to consent changes how privacy, safeguarding and follow-up are arranged.

Current migraine with aura is UKMEC 4 for every combined hormonal route; offer eligible alternatives rather than using a patch or ring to bypass the classification.

Enzyme induction reduces CHC, POP and implant effectiveness but does not reduce copper IUD, LNG-IUD or DMPA effectiveness; apply interaction guidance separately from UKMEC safety.

Unexplained heavy bleeding, a breast mass or liver disease should not be attributed automatically to contraception.

Oestrogen risk pattern

Migraine aura, smoking from age 35, hypertension, VTE history and early postpartum state require exact CHC classification.

Interaction risk

Enzyme induction, lamotrigine and medicines with teratogenic potential require contraceptive and reciprocal drug-effect review.

Autonomy and safety

Private discussion may reveal reproductive coercion, adherence barriers, confidentiality needs or a desire for a method hidden from others.

Investigation priorities

01
Focused medical and medicine historyFirst step

Identify UKMEC conditions, interactions, postpartum state and non-contraceptive treatment goals.

Management branches

Shared-choice pathwayStart with goals before method labels

A person asks for contraception without having selected a method.

  1. Clarify pregnancy intentions, desired duration, effectiveness priority, bleeding preference, privacy, reversibility and STI prevention.
  2. Screen medical eligibility and medicines, then present all suitable methods with typical-use demands, benefits, common adverse effects and serious warning symptoms.

Key medicines

Combined hormonal contraceptionUse the licensed daily pill, weekly patch or vaginal-ring schedule, including a standard or evidence-based tailored hormone-free interval selected for that formulation.Check migraine aura, smoking from age 35, blood pressure, BMI, VTE and arterial risk, postpartum state, liver disease, breast cancer and interacting medicines.
Progestogen-only and intrauterine optionsUse the formulation-specific POP schedule, DMPA interval, implant duration or device duration; instructions are not interchangeable within the class.Current breast cancer, unexplained bleeding, infection or uterine anatomy, enzyme induction and product-specific duration require separate assessment. Enzyme induction can reduce CHC, POP and implant effectiveness; copper IUD, LNG-IUD and DMPA effectiveness is not reduced.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom